Anteotech Ltd · ASX:ADO
Anteotech — Investor Presentation (April 2021)
38 slides from Anteotech's investor presentation, Apr 28, 2021
Slide 1: ASX Announcement: Investor Presentation
ASX Announcement For personal use only 28 April 2021 Investor Presentation AnteoTech Ltd (ASX: ADO) (“AnteoTech” or “the Company”) is pleased to provide shareholders and the market with the attached updated Investor Presentation. This announcement has been authorised for release by the Board. For mo
Slide 2: AnteoTech Investor Presentation Update
For personal use only AnteoTech Ltd (ASX:ADO) Investor Presentation Update 26 April 2021 Jack Hamilton, Chair Derek Thomson, CEO 1
Slide 3: Disclaimer
For personal use only DISCLAIMER The purpose of the presentation is to provide an update of the business of AnteoTech Ltd (ASX:ADO). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these sl
Slide 4: AnteoTech Investor Highlights
ANTEOTECH INVESTOR HIGHLIGHTS Diversified investment opportunity with high growth potential in high impact sectors For personal use only Unique, proprietary nano- Proven product AnteoBind in market – Integrated in Ellume Home Test - FDA EUA polymer technology Proof of concept delivered across Life S
Slide 5: AnteoTech Snapshot Today
ANTEOTECH SNAPSHOT TODAY For personal use only • Strong financial position with growing revenues H1 FY2021 & strong cash balance $6.4M3 STRONG IP • AnteoBind key component in Ellume’s FDA EUA authorised POSITION COVID-19 Antigen Home test now in US market1 +550% YOY 2 CASH • Delivering AnteoTech COV
Slide 6: AnteoTech Snapshot
ANTEOTECH SNAPSHOT For personal use only Headquartered in Brisbane, Australia CORPORATE OVERVIEW: As at 23/04/2021 ASX code ADO SHARE PRICE & VOLUME (APR 2020 - APR 2021): Cash (as at 31 Dec 2020) ~$6.43m Market Cap (at 0.41 $/per share) $777.7m 52 week high - low ($/share) 0.010 – 0.415 Shares on i
Slide 7: AnteoTech Board & Management
ANTEOTECH BOARD & MANAGEMENT For personal use only Jack Hamilton Geoff Cumming Christopher Parker Derek Thomson Duncan Cornish Chair NED NED CEO CFO/ Co. Sec Experienced Chair and Non Has over 20 years’ experience in Has over 20 years of experience Has over 20 years of experience More than 20 years’
Slide 8: Life Science
For personal use only Life Science 7
Slide 9: One Versatile Platform – Multiple Tests
ONE VERSATILE PLATFORM – MULTIPLE TESTS For personal use only Europium LFIA Reader & Strip Design • COVID-19 Antigen Test- Development completed - CE Mark received April 2021 • COVID-19 Flu A&B - In development • Sepsis - In early development • Designed for Use at Point-of-Care (POC), Border/ Travel
Slide 10: Integrated Lifescience Business Model
INTEGRATED LIFESCIENCE BUSINESS MODEL For personal use only • Acceleration of assay development platform & ISO certification in 2020 Assay Development • AnteoTech COVID-19 Antigen Rapid Test 1 (ART) initiated March 2020 & achieved CE approval begin April 21 AnteoBind • US approval & contracts for cu
Slide 11: Life Science Value Pipeline
LIFE SCIENCE VALUE PIPELINE For personal use only AnteoTech Lateral Flow Assay Test Lateral Flow Raw Materials Test Reader Pipeline – Utilising Reader Platform Product COVID-19 Antigen Rapid COVID-19 Flu A/B AnteoBind™ COVID-19 Saliva Test Sepsis Quantitative Test Reader Test (ART) Multiplex Test Na
Slide 12: Anticipated Development Timeline 2021
ANTICIPATED DEVELOPMENT TIMELINE 2021 For personal use only 2021 1 JAN FEB MAR APR MAY JUN JUL AUG SEP AnteoTech COVID-19 Operon1 Lab Trial EU CE Mark 3 EU CE Mark ART manufacturing VIDRL 2 Submission Updated scale up EU Market Launch Clinical Trials AUS TGA + COVID-19 Saliva - Saliva Submission Rev
Slide 13: COVID-19 Antigen Rapid Test – On Brink of Commercial Launch
ANTEOTECH COVID-19 ANTIGEN RAPID TEST – ON BRINK OF COMMERCIAL LAUNCH For personal use only Medical Device Development Pathway Phase 1: Phase 2: Design LIFE SCIENCE Phase 3: Design Phase 4: Production Phase 5: Market Feasibility ✓ Verification ✓ Validation ✓ Validation ✓ Launch ENERGY • CE Mark regi
Slide 14: Growth in Lateral Flow Market & COVID-19
GROWTH IN LATERAL FLOW MARKET & COVID-19 For personal use only Lateral Flow Assay (LFA) Market (Excludes COVID-19) • Market forecast to grow to USD 8.7 billion by 2023 from USD USD $Billions 7.0 billion in 2019 7.7% CAGR 2019-2023 • COVID-19 alters profile of the market significantly • Reports sugge
Slide 15: What Sets AnteoTech's Technology Apart
WHAT SETS ANTEOTECH’S TECHNOLOGY APART Combining AnteoBind technology with activated Europium achieves the For personal use only high sensitivity needed for COVID-19 • COVID-19 Antigen Rapid Test uses • Very high dynamic signal range and AnteoBind activated Europium intensity2 • Consistent gentle bi
Slide 16: Leveraging Current Development
LEVERAGING CURRENT DEVELOPMENT Investment in the current test platform could instigate a number For personal use only of leverage plays that will accelerate revenue Test suite enabled on different reader platforms designed for market segments Current Tests • In field testing – military / refugee / c
Slide 17: Energy
For personal use only Energy 16
Slide 18: Enabling High Energy Batteries
ENABLING HIGH ENERGY BATTERIES For personal use only • High energy silicon anodes are the future • Silicon swells up to 300% of its size when charged • Silicon needs coating and elastic binders • AnteoTech → enabling high silicon content anodes through proprietary coatings and binder technology Ener
Slide 19: Lithium-Ion Battery a Changing Market
LITHIUM-ION BATTERY A CHANGING MARKET For personal use only The industry standard material for anodes, graphite, has reached its limits but increasing silicon content in battery anodes equates to higher electrical storage capacity & potentially lower cost AnteoTech: • Developing products (silicon co
Slide 20: AnteoTech Addressing the Challenge
ANTEOTECH ADDRESSING THE CHALLENGE For personal use only AnteoTech’s technology contributes to lithium-ion battery cells ultimately aiming to enable up to 75% higher capacity vs. conventional graphite cells AnteoTech – AnteoX About Lithium-ion batteries and how they work • AnteoX enhances the perfor
Slide 21: AnteoTech's Silicon Enhancing Technology AnteoX
ANTEOTECH’S SILICON ENHANCING TECHNOLOGY ANTEOX™ For personal use only How AnteoTech’s combined technology solutions could affect battery energy storage as a result of enhanced silicon integration • Global desire to increase the silicon content in anodes to increase the amount of energy batteries ab
Slide 22: Lithium Ion Battery Market
LITHIUM ION BATTERY MARKET For personal use only As energy storage demands increase and technology advances, demand for silicon demand for high silicon content lithium-ion batteries is expected to grow significantly- exactly where AnteoTech’s IP application is adding value Lithium-ion battery market
Slide 23: Near Term Energy Development Program
NEAR TERM ENERGY DEVELOPMENT PROGRAM For personal use only In discussion with & have work programs with several companies spanning the global value chain - including large chemical companies & battery manufacturers - evaluating and exploring silicon composite projects and AnteoX (cross-linker additi
Slide 24: AnteoTech Investor Highlights
ANTEOTECH INVESTOR HIGHLIGHTS Diversified investment opportunity with high growth potential in high impact sectors For personal use only Unique, proprietary nano- Proven product AnteoBind™ in market – Integrated in Ellume Home Test - FDA EUA polymer technology Proof of concept delivered across Life
Slide 25: Capital Raise
For personal use only Capital Raise 24
Slide 26: Overview
OVERVIEW For personal use only Description Details Description Details • $12.0m Placement to professional and Current Shares on Issue 1,874,038,799 sophisticated investors under s.708 (8) and (11) of the Corporations Act 2001 (Cth) Options & Performance Rights on Issue1 104,449,760 • Company utilisi
Slide 27: Indicative Timetable
INDICATIVE TIMETABLE For personal use only Description Date (2021) Trading Halt 9am Monday, 26 April Bookbuild conducted for the Monday, 26 April – Tuesday, 27 April Placement Record Date for SPP Tuesday, 27 April Announcement of Placement and Wednesday, 28 April SPP SPP Offer opens Tuesday, 4 May S
Slide 28: Use of Funds
USE OF FUNDS For personal use only Source of Funds Placement funds (A$m) Use of Funds Fund Use (A$m) Working capital for COVID-19 Antigen Rapid Capital Raising 12.0 6.0 Test rollout Acceleration of assay pipeline, including COVID 3.0 Multiplex and Sepsis Test Organisational development in support of
Slide 29: Post Offer Pro-Forma Balance Sheet
POST OFFER PRO-FORMA BALANCE SHEET For personal use only ADO Balance Sheet ($) 31 December 2020 Impact of the Offer Pro Forma 31 December 2020 Assets Current assets 6,518,014 12,000,000 18,518,014 Non-current assets 471,661 - 471,661 Total assets 6,989,675 12,000,000 18,989,675 Liabilities Current l
Slide 30: AnteoTech Ltd
For personal use only AnteoTech Ltd (ASX:ADO) Derek Thomson Dr Jack Hamilton Chief Executive Officer Chairman 29
Slide 31: Appendix
For personal use only Appendix 30
Slide 32: About AnteoTech's Technology
ABOUT ANTEOTECH’S TECHNOLOGY For personal use only LIFE SCIENCE • Solving surface chemistry challenges in the Life Improves diagnostic assay Science and Energy sectors with proprietary performance and greater QC, ‘nano polymer’ ENERGY biomarker candidate screening & efficacy-measurement in drug By s
Slide 33: Revenue Generating Life Science Platforms
3 REVENUE GENERATING LIFE SCIENCE PLATFORMS For personal use only • Key Value Driver for AnteoTech High Sensitivity AnteoTech COVID-19 Antigen Rapid Test • Executing on COVID Rapid Antigen Test and Proof of Concept success for COVID + Flu, Sepsis development COVID-19 & Flu A + Flu B multiplex ASSAY
Slide 34: AnteoBind & Lateral Flow Test Principles
ANTEOBIND & LATERAL FLOW TEST PRINCIPLES For personal use only Protein-Particle Conjugate for detection Lateral Flow Test Model in the test is the key component that impacts Analyte Sample pad Conjugate pad Membrane Test line Control line Wick an assay performance Imaging of an antibody Image source
Slide 35: AnteoBind & Lateral Flow Test Principles
ANTEOBIND & LATERAL FLOW TEST PRINCIPLES For personal use only HOW ANTEOBIND WORKS Antibody • Metal ion polymers are positively charged • Stable activated surfaces are ready to use & Protein stable in solution >1 year • Active binding is effective and reproducible multi-point coordination binding An
Slide 36: Global Challenge of Sepsis
GLOBAL CHALLENGE OF SEPSIS For personal use only • Sepsis: preventable, life-threating condition marked by severe organ dysfunction. • 2017 studies estimate 49 million cases and 11 million sepsis-related deaths worldwide; ~ 20% accounting for 20% of all global deaths global deaths due to sepsis • Ea
Slide 37: AnteoX Additive Stabilizes 70% Micro-Silicon Anode
ANTEOX ADDITIVE STABILIZES 70% MICRO-SILICON ANODE For personal use only • Following recent work demonstrating 26% increase in capacity, further development work has progressed (Fig. 1). Addition of AnteoX can significantly uplift the performance of high silicon content anodes, especially if the bin
Slide 38: Technology Development Roadmap at Anode Coating Level
TECHNOLOGY DEVELOPMENT ROADMAP AT ANODE COATING LEVEL For personal use only Silicon anode system Provide licenses Silicon active materials 4th to anode system product Partnering for Advanced binder 3rd manufacturing product Manufacture & 2nd and distribution partnership product AnteoX Additives hybr